(Q43727233)

26 November 2017

title

Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy (English)

1 reference

26 November 2017

M Gavatha

1

1 reference

26 November 2017

I Ioannou

series ordinal

2

1 reference

26 November 2017

A S Papavasiliou

series ordinal

3

1 reference

26 November 2017

language of work or name

1 reference

15 March 2011

1 reference

26 November 2017

1 reference

26 November 2017

volume

20

1 reference

26 November 2017

issue

4

1 reference

26 November 2017

page(s)

691-693

1 reference

The neurobehavioural comorbidities of epilepsy: can a natural history be developed?

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

The use of antiepileptic drugs--principles and practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

Early identification of refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

The effects of refractory epilepsy on intellectual functioning in children and adults. A longitudinal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

Newer antiepileptic drugs and cognitive issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

Lacosamide: a review of preclinical properties.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

Newly Diagnosed Epilepsy in Children: Presentation at Diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

Seeking a mechanism of action for the novel anticonvulsant lacosamide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

A Pooled Analysis of Lacosamide Clinical Trial Data Grouped by Mechanism of Action of Concomitant Antiepileptic Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.02.005

10.1016/J.YEBEH.2011.02.005

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference